REAL-LIFE EFFECTIVENESS OF NATALIZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): A REGISTRY ANALYSIS

被引：0
|
作者：
Danko, D. [1 ]
Manca, A. [2 ]
Mor, Z. [3 ]
Csepany, T. [4 ]
机构：
[1] Corvinus Univ Budapest, Budapest, Hungary
[2] Univ York, York YO10 5DD, N Yorkshire, England
[3] Ideas Solut, Budapest, Hungary
[4] Univ Debrecen, H-4012 Debrecen, Hungary
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.334
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND3
引用
收藏
页码：A56 / A57
页数：2
相关论文
共 50 条
  • [1] REGIONAL EFFICACY OF NATALIZUMAB TREATMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
    Doshi, Anisha
    Voysey, Zanna
    Bunting, Eva
    Malik, Muzaffar
    Rashid, Waqar
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11):
  • [2] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [3] Natalizumab for relapsing-remitting multiple sclerosis
    Horga, A.
    Tintore, M.
    NEUROLOGIA, 2011, 26 (06): : 357 - 368
  • [4] Relationship of natalizumab exposure and MRI response in patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
    Muralidharan, K. Kandadi
    Steiner, D.
    Elkins, J.
    Ho, P. -R.
    Amarante, D.
    Koendgen, H.
    Evans, K.
    Mikol, D.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 811 - 811
  • [5] Natalizumab in spinal relapsing-remitting multiple sclerosis
    Zecca, C.
    Kamm, C.
    Riccitelli, G. C.
    Heldner, M.
    Caporro, M.
    Gobbi, C.
    JOURNAL OF NEUROLOGY, 2014, 261 : S303 - S303
  • [6] Natalizumab in spinal relapsing-remitting multiple sclerosis
    Zecca, C.
    Kamm, C.
    Riccitelli, G. C.
    Heldner, M.
    Caporro, M.
    Gobbi, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 457 - 457
  • [7] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Cavit Boz
    Serkan Ozakbas
    Murat Terzi
    Rana Karabudak
    Serhan Sevim
    Recai Turkoglu
    Aysun Soysal
    Belgin Petek Balcı
    Hüsnü Efendi
    Ömer Faruk Turan
    Nur Yüceyar
    Mehmet Fatih Yetkin
    Serap Zengin Karahan
    Meltem Demirkıran
    Sibel Guler
    Kadriye Agan
    Nefati Kıylıoğlu
    Cavid Baba
    Asli Tuncer
    Mesrure Köseoğlu
    Neurological Sciences, 2023, 44 : 2121 - 2129
  • [8] Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis
    Stephanie R. Earnshaw
    Jonathan Graham
    MerriKay Oleen-Burkey
    Jane Castelli-Haley
    Kenneth Johnson
    Applied Health Economics and Health Policy, 2009, 7 (2) : 91 - 108
  • [9] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Ozakbas, Serkan
    Terzi, Murat
    Karabudak, Rana
    Sevim, Serhan
    Turkoglu, Recai
    Soysal, Aysun
    Balci, Belgin Petek
    Efendi, Husnu
    Turan, Omer Faruk
    Yuceyar, Nur
    Yetkin, Mehmet Fatih
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Guler, Sibel
    Agan, Kadriye
    Kiylioglu, Nefati
    Baba, Cavid
    Tuncer, Asli
    Koseoglu, Mesrure
    NEUROLOGICAL SCIENCES, 2023, 44 (06) : 2121 - 2129
  • [10] Cost Effectiveness of Glatiramer Acetate and Natalizumab in Relapsing-Remitting Multiple Sclerosis
    Earnshaw, Stephanie
    Graham, Jonathan
    Oleen-Burkey, MerriKay
    Castelli-Haley, Jane
    Johnson, Kenneth
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2009, 7 (02) : 91 - 108
12345